首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Expert Opinion On Drug Safety

Expert Opinion On Drug Safety杂志,由Taylor and Francis Ltd.出版,于2002年创刊,Bimonthly,出版语言English,ISSN:1474-0338,E-ISSN:1744-764X。

投稿咨询
Expert Opinion On Drug Safety
Expert Opinion On Drug Safety
Expert Opinion On Drug Safety
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
3区
影响因子
3
CiteScore
6.1
期刊收录
SCI、SCIE

Expert Opinion On Drug Safety(中文译名:《药品安全专家意见》),ISSN:1474-0338,EISSN:1744-764X,是Taylor and Francis Ltd.出版的国际性学术期刊,创刊于2002年,以Bimonthly形式稳定发行,2026年总发文量约200篇。该刊采用非OA开放访问,学科归属为医学 - 药学。该刊是医学、药学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达3,2025年期刊CiteScore为6.1,2025年期刊自引率约6.7%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Expert Opinion On Drug Safety长期聚焦医学、药学及相关产业的技术应用前沿,平均审稿周期较慢,6-12周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、药学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAItaly、England、Spain、CHINA MAINLAND、France、GERMANY (FED REP GER)等为核心发文国家与地区;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)HARVARD UNIVERSITY、UNIVERSITY OF BOLOGNA、CATHOLIC UNIVERSITY OF THE SACRED HEART、CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED、UNIVERSITY OF LONDON、UNIVERSITY OF MILAN等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q2 169 / 356

52.7

学科:PHARMACOLOGY & PHARMACY SCIE Q2 135 / 356

62.22

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q2 134 / 352

62.1

学科:PHARMACOLOGY & PHARMACY SCIE Q3 189 / 353

46.6


中国学者近期发文

1
Safety concerns associated with various types of statins: a disproportionality analysis of the FAERS databas

Author:Zeng, Yi; Tian, Xiaona; Jiang, Jiazhen; Pan, Wenhao; Liu, Bingshuo; Dai, Dandan; Zhou, Lisi; Zeng, Wenling; Chen, Yizhen; Liu, Jiaming

Journal: EXPERT OPINION ON DRUG SAFETY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2026.2656375

2
Risk of active tuberculosis and herpes zoster with tumor necrosis factor inhibitor treatment in adults with autoimmune disease conditions: a systematic trial sequential analysis of randomized placebo-controlled clinical trial

Author:Okoli, George N.; Cowling, Benjamin J.; Askin, Nicole; Harper, Diane M.; Van Caeseele, Paul

Journal: EXPERT OPINION ON DRUG SAFETY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2026.2642872

3
Direct oral anticoagulants combined with antiplatelet in the treatment of acute coronary syndrome and atrial fibrillation patients undergoing percutaneous coronary intervention or complicating acute coronary syndrome: a systematic review and meta-analysi

Author:Bai, Lexie; Lin, Shuyun; Liu, Delong; Zhang, Bingbing; Liu, Lili; Zhao, Guojun

Journal: EXPERT OPINION ON DRUG SAFETY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2596236

4
Dipyridamole-associated pulmonary edema: discovery of a new potential adverse reaction signal based on the FAERS databas

Author:Dong, Xiaomin; Guo, Guimu; Zhou, Jintuo; Chen, Tingting; Niu, Peiguang; Zeng, Xiaoping; Pan, Ruoxuan; Zhang, Jinhua

Journal: EXPERT OPINION ON DRUG SAFETY. 2026; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2026.2618005

5
Two first-generation KRAS inhibitor safety profiles: a disproportionality analysis of individual reports from the FDA adverse event reporting syste

Author:Zhang, Ying; Tong, Shuhua; Wan, Li

Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2499219

6
Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS databas

Author:Zhang, Si-Han; Xu, Jin-Zhou; Zeng, Na; Xia, Zhi-Yu; Miao, Lin-Tao; Zhang, Ci; Wang, Shao-Gang; Xia, Qi-Dong

Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2496434

7
Analysis of the relationship between histamine H1 receptor antagonists and broad dementia events using the FAERS, JADER, and CVAR database

Author:Kan, Jingjing; Chen, Yechao; Gu, Qiaoling; Hu, Na; Qiao, Yanli; Chen, Yawen; Chen, Dayu; Zhang, Haixia

Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2517232

8
Comprehensive post-marketing safety analysis of tildrakizumab: insights from the FDA adverse event reporting syste

Author:Zhao, Kaidi; Xiao, Shengxiang; Zhao, Yang; Tu, Chen

Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2520422

9
Infection-related adverse events comparison of bortezomib, carfilzomib and ixazomib: a pharmacovigilance study based on FAER

Author:Xiang, Chenhuan; Guo, Rongrong; Ti, Juanjuan; Zhang, Shaoli; Wang, Tao

Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2494692

10
Comparative safety analysis of baloxavir marboxil and oseltamivir based on the FAERS databas

Author:Tu, Yingqiu; Lai, Xin; Wan, Qing; Xu, Tiantian

Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2495854


在线咨询

Expert Opinion On Drug Safety

国际简称:EXPERT OPIN DRUG SAF参考译名:药品安全专家意见

年发文量:200 CiteScore:6.1 是否预警:否 Gold OA文章占比:2.02% 研究类文章占比:79.00%

杂志社联系方式:INFORMA HEALTHCARE, TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON, ENGLAND, EC2A 4LQ

Expert Opinion On Drug Safety